知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.029 秒)

    Ecarin prothrombin protease and methods
    4.
    发明授权
    Ecarin prothrombin protease and methods 有权
    Ecarin凝血酶原蛋白酶和方法

    公开(公告)号：US06413737B1

    公开(公告)日：2002-07-02

    申请号：US09608790

    申请日：2000-06-30

    申请人： David R. Olsen ,  Jeff Prior ,  Louis C. Sehl ,  Donald G. Wallace

    发明人： David R. Olsen ,  Jeff Prior ,  Louis C. Sehl ,  Donald G. Wallace

    IPC分类号： C12P2106

    CPC分类号： C12N9/6429 ,  C12N9/6418 ,  C12Y304/21005

    摘要： New forms of ecarin, a procoagulant protein from Echis carinatus venom, are described, as are polynucleotides encoding the new proteins, methods for production of the new proteins, and methods for activation of prothrombin using the new proteins. The new ecarins comprise a serine at position 396 of the protein. The new proteins may be used for activation of prothrombin, and are particularly useful for the production of recombinant thrombin.

    摘要翻译： 描述了新形式的ecarin，来自Echis carinatus毒液的促凝血蛋白，以及编码新蛋白质的多核苷酸，新蛋白质的生产方法，以及使用新蛋白质激活凝血酶原的方法。 新的ecarin在蛋白质的396位置包含丝氨酸。 新蛋白质可用于激活凝血酶原，并且特别可用于生产重组凝血酶。

    Method for bonding or fusion of biological tissue and material
    6.
    发明授权
    Method for bonding or fusion of biological tissue and material 失效
    生物组织和材料的粘合或融合方法

    公开(公告)号：US5749895A

    公开(公告)日：1998-05-12

    申请号：US303336

    申请日：1994-09-06

    申请人： Philip N. Sawyer ,  Donald G. Wallace ,  Ronald K. Yamamoto

    发明人： Philip N. Sawyer ,  Donald G. Wallace ,  Ronald K. Yamamoto

    IPC分类号： A61B17/00 ,  A61B17/072 ,  A61B17/11 ,  A61B18/00 ,  A61B18/22 ,  A61F2/00 ,  A61L15/32 ,  A61L27/24 ,  A61B17/04

    CPC分类号： A61B18/22 ,  A61B17/00491 ,  A61B17/11 ,  A61L15/32 ,  A61L15/325 ,  A61L27/24 ,  A61B17/07292 ,  A61B18/042 ,  A61B2017/00504 ,  A61F2310/00365

    摘要： Biological materials are joined, repaired or fused by heating the material in proximity to a mechanical support. Preferably, the mechanical support comprises a patch or bridge structure. In the most preferred embodiment, the patch is formed from collagen having a thickness from between 2 to 30 mils, and most preferably from 2 to 15 mils thick. Preferably, the patch or support structure contains holes or interlock vias which permit the coagulum to form a mechanical bond therewith, whether preformed or generated by an electrical energy source during welding. The preferred method comprises the steps of: first, placing the patch in contact with the materials to be joined, supplying energy to the tissue in an amount sufficient to form a coagulum at the surface of the patch, and finally, permitting the coagulum to form a mechanical bond with the support or patch. The preferred energy source is an inert gas beam RF energy source, with the preferred gas being argon, and the preferred energy range from about 3 to 80 watts. Support structures are utilized in connection with the welding of collapsible structures.

    摘要翻译： 生物材料通过加热机械支撑附近的材料而接合，修理或熔合。 优选地，机械支撑件包括贴片或桥结构。 在最优选的实施方案中，贴剂由厚度为2至30密耳，最优选2至15密耳厚的胶原形成。 优选地，贴片或支撑结构包含孔或互锁通孔，其允许凝结物与其形成机械结合，无论是在焊接期间由电能源预先形成还是由电能源产生。 优选的方法包括以下步骤：首先，使贴片与待连接的材料接触，向组织供应足以在贴剂表面形成凝结物的量，最后允许凝结物形成 与支撑件或贴片的机械粘合。 优选的能量源是惰性气体射束能量源，优选的气体为氩气，优选的能量范围为约3-80瓦特。 支撑结构与可折叠结构的焊接有关。

    Method of preparing fibronectin and antihemophilic factor
    9.
    发明授权
    Method of preparing fibronectin and antihemophilic factor 失效
    纤连蛋白和抗血友病因子的制备方法

    公开(公告)号：US4341764A

    公开(公告)日：1982-07-27

    申请号：US127340

    申请日：1980-03-05

    申请人： Donald G. Wallace ,  Phillip M. Schneider ,  John L. Lundblad

    发明人： Donald G. Wallace ,  Phillip M. Schneider ,  John L. Lundblad

    IPC分类号： C07K14/745 ,  A61K35/14 ,  A61K38/00 ,  A61K38/16 ,  C07K14/435 ,  C07K14/755 ,  C07K14/76 ,  C07K14/78 ,  C07K16/00

    CPC分类号： C07K14/78 ,  C07K14/755 ,  A61K38/00 ,  Y10S530/83 ,  Y10S530/831

    摘要： Methods are disclosed for obtaining fibronectin and antihemophilic factor in commercial quantities from blood plasma. In the disclosed methods a blood plasma fraction containing fibronectin and antihemophilic factor is isolated from blood plasma and then solubilized in an aqueous medium. The solution is acidified and chilled at a temperature sufficient to form an acid-chill precipitate containing a major proportion of the fibronectin and a solution containing a major proportion of the antihemophilic factor of the blood plasma fraction. Fibronectin and antihemophilic factor are then isolated respectively from the precipitate and solution.

    摘要翻译： 公开了从血浆中获得商业数量的纤连蛋白和抗血友病因子的方法。 在公开的方法中，从血浆中分离含有纤连蛋白和抗血友病因子的血浆级分，然后溶解在水性介质中。 将溶液酸化并在足以形成含有主要比例的纤连蛋白的酸冷沉淀物的温度下冷冻，以及含有主要比例的血浆级分的抗血友病因子的溶液。 然后从沉淀物和溶液中分离纤连蛋白和抗血友病因子。